Effects of an oral contraceptive containing estradiol valerate and dienogest on circulating androgen levels and acne in young patients with PCOS: an observational preliminary study
This observational study found that estradiol valerate/dienogest treatment improved acne in 52.8% of young PCOS patients and increased SHBG levels, though testosterone levels did not significantly decrease.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
My notes (saved in your browser only)
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (26)
- Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate via openalex
- Pharmacological profile of progestins via openalex
- Pharmacological profile of progestins via openalex
- Preliminary study on the effect of four-phasic estradiol valerate and dienogest (E2V/DNG) oral contraceptive on the quality of sexual life via openalex
- Review of the safety, efficacy and patient acceptability of the combined dienogest/estradiol valerate contraceptive pill via openalex
- The use of newer progestins for contraception via openalex
- doi:10.1080/1362518042000221508 via openalex
- doi:10.1001/archderm.134.4.454 via openalex
- doi:10.1055/s-2007-1021407 via openalex
- W76793071 via openalex
- W2402629557 via openalex
- doi:10.1016/0010-7824(95)00098-u via openalex
- doi:10.1016/0010-7824(90)90034-s via openalex
- doi:10.1016/0002-9378(87)90238-9 via openalex
- doi:10.1056/nejm199509283331307 via openalex
- doi:10.1210/er.2002-0015 via openalex
- doi:10.1016/s0015-0282(16)53212-9 via openalex
- doi:10.1016/j.fertnstert.2003.10.004 via openalex
- doi:10.1136/adc.77.1.89 via openalex
- doi:10.3109/13625180903585431 via openalex
- doi:10.1111/j.1365-2265.1985.tb01061.x via openalex
- doi:10.1016/j.maturitas.2012.01.018 via openalex
- doi:10.1016/s0029-7844(02)02725-4 via openalex
- doi:10.1210/jc.2007-2437 via openalex
- doi:10.1016/j.rigp.2004.05.001 via openalex
- doi:10.1111/j.1600-0846.2011.00542.x via openalex
Cited by (4)
- Estradiol Valerate vs Ethinylestradiol in Combined Oral Contraceptives: Effects on the Pituitary-Ovarian Axis 2022
- Overview of the therapeutic possibilities of combined oral contraceptive containing estradiol valerate and dienogest 2019
- Use of oral contraceptives for management of acne vulgaris and hirsutism in women of reproductive and late reproductive age 2018
- Noncontraceptive benefits of the estradiol valerate/dienogest combined oral contraceptive: a review of the literature 2014
Source provenance
- openalex
- last seen: 2026-05-11T07:08:39.058960+00:00
- pubmed
- last seen: 2026-10-08T21:12:29.265612+00:00